Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp alfa in HMGA2+ TNBC
NCT04489940Phase 2Terminated
- Sponsor
- EMD Serono
- Start
- Oct 2020
- Primary completion
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 6
01
Overview
A Phase 2 trial of bintrafusp alfa in triple-negative breast cancer (TNBC), sponsored by EMD Serono. Started Oct 2020; status: terminated.
02
Drugs
bintrafusp alfa
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04489940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04489940.